ESAIY Stock - Eisai Co., Ltd.
Unlock GoAI Insights for ESAIY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $789.40B | $741.75B | $744.40B | $756.23B | $645.94B |
| Gross Profit | $620.59B | $586.42B | $566.57B | $581.39B | $484.63B |
| Gross Margin | 78.6% | 79.1% | 76.1% | 76.9% | 75.0% |
| Operating Income | $54.38B | $53.41B | $40.04B | $53.75B | $53.22B |
| Net Income | $46.43B | $42.41B | $55.43B | $47.95B | $41.94B |
| Net Margin | 5.9% | 5.7% | 7.4% | 6.3% | 6.5% |
| EPS | $40.94 | $36.97 | $48.33 | $41.82 | $36.74 |
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Visit WebsiteEarnings History & Surprises
ESAIYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | — | — | — | — |
Q4 2025 | Nov 6, 2025 | — | $0.00 | — | — |
Q3 2025 | Aug 4, 2025 | — | — | — | — |
Q3 2025 | Aug 4, 2025 | — | — | — | — |
Q2 2025 | May 13, 2025 | — | — | — | — |
Q1 2025 | Feb 4, 2025 | — | — | — | — |
Q4 2024 | Nov 8, 2024 | — | — | — | — |
Q3 2024 | Aug 2, 2024 | — | $0.06 | — | — |
Q2 2024 | May 15, 2024 | — | $0.08 | — | — |
Q1 2024 | Feb 6, 2024 | — | $0.04 | — | — |
Q3 2023 | Sep 30, 2023 | — | $0.02 | — | — |
Q2 2023 | Jun 30, 2023 | — | $0.12 | — | — |
Q1 2023 | Mar 31, 2023 | — | $0.11 | — | — |
Q4 2022 | Dec 31, 2022 | — | $0.06 | — | — |
Q3 2022 | Sep 30, 2022 | — | $0.02 | — | — |
Q2 2022 | Jun 30, 2022 | — | $0.17 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.09 | — | — |
Q4 2021 | Dec 31, 2021 | — | $0.11 | — | — |
Q3 2021 | Sep 30, 2021 | — | $0.03 | — | — |
Latest News
Frequently Asked Questions about ESAIY
What is ESAIY's current stock price?
What is the analyst price target for ESAIY?
What sector is Eisai Co., Ltd. in?
What is ESAIY's market cap?
Does ESAIY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ESAIY for comparison